Immutep Limited in The Rocks, Sydney | Biotechnology company

Immutep Limited

Locality: The Rocks, Sydney

Address: Level 12, 95 Pitt Street, SYDNEY 2000 The Rocks, NSW, Australia

Website: http://www.immutep.com

Likes: 675

Add/Update information

Reviews

Tags

• Medical and health
• Biotechnology company

25.01.2022 Immutep Limited will is pleased to announce more mature interim data from its phase II TACTI-002 study of efti has been accepted as a late breaker poster presentation and poster walk for highly scored abstracts at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary 2020 Annual Meeting. The poster presentation will be available from Monday 9 November 2020, 8am US EST. #SITC20 is the world’s leading member society of medical professionals dedicated to advancing ca...ncer #immunotherapy and biological therapy. Its Annual Meeting is a multidisciplinary educational and interactive conference focused on improving cancer patient outcomes. #biotechnology #oncology #clinicaltrials See more

19.01.2022 Immutep Limited CEO Marc Voigt spoke with Stockhead about the newly announced EAT COVID trial. #coronavirus #COVID19 #biotechnology

12.01.2022 Immutep Limited has signed an agreement with the University Hospital Pilsen, Czech Republic to enable an investigator-initiated randomised Phase II clinical trial evaluating its lead product candidate efti in up to 110 hospitalised patients with COVID-19. The study tests whether the early administration of efti prevents COVID-19 disease progression in adult patients. Initial interim results are expected to be reported from early 2021. ... Immutep CEO, Marc Voigt, said: "We believe efti is currently the only APC activator of its kind being evaluated against COVID-19 in a randomised Phase II trial and that the study will contribute to our further understanding of its potential in infectious diseases in general. #covid19research #coronavirus #covid19 #biotechnology

10.01.2022 Immutep Limited and its partner, Novartis, have been granted a new patent by the Australian Patent Office for LAG525, a humanised form of Immutep’s IMP701 antibody which is out-licensed to Novartis AG. This new Australian patent builds on the corresponding US patents announced in March 2018 and July 2020, a European patent announced in November 2019, and a Japanese patent announced in September 2019. #intellectualproperty #patents #IP

10.01.2022 Thank you to all our shareholders who joined our virtual AGM 2020 today. If you missed the meeting, you can read the Chairman's Address here: https://bit.ly/2Tudvua and the CEO Presentation here: https://bit.ly/3jAEtL4. #biotechnology

02.01.2022 Immutep Limited has entered into a Licence and Collaboration Agreement with Laboratory Corporation of America Holdings, known as LabCorp (NYSE: LH) that will support the development of immuno-oncology products or services. Over the years, Immutep has generated a significant amount of know-how in immuno-oncology, specifically in terms of LAG-3, said Marc Voigt, CEO of Immutep. Immutep is eligible to receive an upfront fee of US$125,000 and potential further commercial mile...stones and service payments. The milestone payments, which consist of up to three payments, are tied to the commercialisation of new drugs or new indications of existing drugs that requires use of an immuno-oncology diagnostic being developed by LabCorp. #biotechnology https://bit.ly/31TvI95 See more